MARKET

RGNX

RGNX

Regenxbio
NASDAQ
14.04
+0.42
+3.08%
Opening 10:07 01/20 EST
OPEN
13.50
PREV CLOSE
13.62
HIGH
14.22
LOW
13.40
VOLUME
176.68K
TURNOVER
--
52 WEEK HIGH
15.84
52 WEEK LOW
5.04
MARKET CAP
710.75M
P/E (TTM)
-4.0548
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RGNX last week (0112-0116)?
Weekly Report · 1d ago
Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)
TipRanks · 5d ago
RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating
TipRanks · 01/13 02:47
Regenxbio rises on data for Duchenne muscular dystrophy candidate
Seeking Alpha · 01/12 16:36
Regenxbio Shares Rise in Premarket As Duchenne Gene Therapy Shows Treatment Benefit
Dow Jones · 01/12 11:24
REGENXBIO Stock Hits New High On Duchenne Trial Data - Will 2026 Be A Transformative Year?
NASDAQ · 01/12 11:23
Weekly Report: what happened at RGNX last week (0105-0109)?
Weekly Report · 01/12 09:41
Reported Sunday, REGENXBIO Highlights 2026 Catalysts As RGX-202 Shows Durable 18-Month Functional Benefit, With FDA PDUFA, BLA Filing, And Multiple Pivotal Readouts Expected
Benzinga · 01/12 08:17
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.